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Abstract
Background: To investigate the predictive value of decreased urine output based on the Risk of renal dysfunction,
Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage renal disease (RIFLE) classification
on contrast- induced acute kidney injury (CA-AKI) in intensive care (ICU) patients.
Methods: All patients who received contrast media (CM) injection for CT scan or coronary angiography during a
3-year period in a 24 bed medico-surgical ICU were reviewed.
Results: Daily serum creatinine concentrations and diuresis were measured for 3 days after CM injection. We identified
23 cases of CA-AKI in the 149 patients included (15.4 %). Patients who developed CA-AKI were more likely to require
renal replacement therapy and had higher ICU mortality rates. At least one RIFLE urine output criteria was observed in
45 patients (30.2 %) and 14 of these 45 patients (31.1 %) developed CA-AKI based on creatinine concentrations. In 30 %
of these cases, urine output decreased or didn’t change after the increase in creatinine concentrations. The RIFLE urine
output criteria had low sensitivity (39.1 %) and specificity (67.9 %) for prediction of CA-AKI, a low positive predictive
value of 50 % and a negative predictive value of 87.2 %. The maximal dose of vasopressors before CM was the only
independent predictive factor for CA-AKI.
Conclusions: CA-AKI is a frequent pathology observed in ICU patients and is associated with increased need for renal
replacement therapy and increased mortality. The predictive value of RIFLE urine output criteria for the development of
CA-AKI based on creatinine concentrations was low, which limits its use for assessing the effects of therapeutic
interventions on the development and progression of AKI.
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Background
Acute kidney injury (AKI) is a frequent pathology in
critically ill patients: a European epidemiological survey
reported that 25 % of patients had transient AKI and
that 10 % of them needed renal replacement therapy
(RRT) during their intensive care (ICU) stay [1, 2]. The
mortality rate associated with AKI ranges from 30 % in
toxic forms to 90 % when associated with multiorgan
failure [1, 3].
The physiopathology of AKI is multifactorial in critic-
ally ill patients and include low systemic blood pressure
[4–6], intravascular hypovolaemia [7], alterations of the
local microcirculation [7, 8], systemic inflammation with
renal leukocyte accumulation [9], ischaemia/reperfusion
processes [10], and direct drug toxicity [11].
Contrast-induced nephropathy is a common cause of
hospital-acquired AKI [12]. The incidence of this condi-
tion varies across studies but it appears to be much
higher in ICU patients [13], varying from 2 to 23 % in a
recent retrospective monocenter study [14, 15].
The pathophysiology of contrast-induced nephropathy
is complex and associates vasoconstriction with renal is-
chaemia, oxidative stresses, inflammation and direct tox-
icity of the iodinated contrast media (CM) on tubular
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cells, leading finally to an increase in serum creatinine
[16, 17]. Identification of contrast-induced nephropathy
in ICU patients is difficult because of the many other
pathological mechanisms complicating critical illness.
For these reasons, Hoste et al. [15] suggested using the
term contrast-associated AKI (CA-AKI) instead of “in-
duced”. CA-AKI is defined by an increase in serum cre-
atinine of 25 % from baseline or ≥0.5 mg/dL within 3
days after CM administration [18]. Because of the high
mortality rate associated with AKI in critically ill pa-
tients, early detection of CA-AKI may be important to
enable therapy to be adapted accordingly. To provide a
uniformly accepted definition of AKI, a classification as-
sociating change in urine output and increase in serum
creatinine has been proposed: the RIFLE (Risk of renal
dysfunction, Injury to the kidney, Failure of kidney func-
tion, Loss of kidney function and End-stage renal dis-
ease) classification [19, 20]. This classification shows the
better robustness and a higher detection rate during the
first 48 h of ICU admission in several studies [20–22].
More recently, the Kidney Disease Improving Global
Outcome (KDIGO) criteria, an alternative to the RIFLE
criteria was developed but short-term and long-term
mortality were similar.
Because intermittent oliguria may turn into persistent
oliguria or evolve into AKI [23, 24] and because AKI
with oliguria or anuria has been reported to be asso-
ciated with a worse outcome compared with patients
with preserved urine output and because urinary out-
put is easy to measure with indwelling urinary cathe-
ters in ICU patients, we hypothesised that the RIFLE
urine output criteria could be an early and predictive
marker of CA-AKI. We, therefore, evaluated the inci-
dence of CA-AKI and the RIFLE urine output criteria




The local ethical committee (ethical committee from the
Intercommunal de Santé Publique du Pays de Charleroi-
OM008) approved this study and informed consent was
waived because of the retrospective nature that required
no intervention. We reviewed the data from all patients
admitted to our 24-bed medico-surgical ICU from 1st
January 2010 to 31st December 2012 who received intra-
venous or intra-arterial CM injection for computed tom-
ography (CT) or coronary angiography.
We included all patients ≥18 years, with an ICU length
stay of minimum 3 days after the CM injection. Exclu-
sion criteria were: renal transplantation, decision to start
RRT before CM injection, end-stage renal disease requir-
ing iterative haemodialysis, another injection of CM 3
days before or after the analysed examination, surgery
within 3 days after the CM injection, incomplete bio-
logical or demographic data.
We recorded the age, sex, weight, diagnosis at ICU ad-
mission (cardiological, including cardiac arrest, myocar-
dial infarction and cardiogenic shock; trauma; sepsis;
suspicion of pulmonary embolism; neurologic, including
subarachnoid or brain haemorrhages or brain tumor; or
other (renal imaging, suspicion of mesenteric ischaemia,
etc.). We also collected the Acute Physiology And
Chronic Health Evaluation (APACHE) II score [25], co-
morbidities known to alter renal function, e.g., diabetes
mellitus, cardiovascular risk factors including ischaemic
cardiomyopathy and/or arterial hypertension, and prior
chronic renal failure defined by a creatinine concentra-
tion ≥1.5 mg/dL [15]. We also recorded the need for
RRT during the ICU hospitalisation because of classical
complications of renal failure, i.e., overload, acidosis,
hyperkalaemia or hyperuremia [26], the length of ICU
and hospital stays and the ICU mortality.
Any treatments that can be involved in the develop-
ment of AKI were also noted, including diuretics,
non-steroidal anti-inflammatory drugs, angiotensin-
converting enzyme inhibitors or angiotensin II receptor
blockers, aminoglycosides and glycopeptides. Maximum
doses of vasoactive drugs (norepinephrine and dobuta-
mine) before and every day after CM administration were
recorded.
Any specific preventive therapy given before the CM
was also noted: e.g., administration of N-acetylcysteine
or specific fluid administration. However, no protocol
for CA-AKI prevention was applied routinely in our
ICU during the study period. The CM used during the
study period were all non-ionic, and iso-osmolar or low-
osmolar. Angiography examinations were exclusively
performed with a non-ionic, iso-osmolar contrast agent.
We also recorded the quantity of CM injected by body
weight.
Biological data
We retrieved the biological data that was closest the in-
jection of CM and at days 1, 2 and 3 after injection.
These data included: haematocrit, blood urea, creatinine
(Abbott Laboratories, Illinois, USA; coefficient of
variation :0.6 % or 0.1 mg/dL), bicarbonate, natremia, C-
reactive protein, and creatinine phosphokinase concentra-
tions. Glomerular filtration rate was estimated as the mea-
sured and estimated glomerular filtration rate (MDRD)
[27]. We also collected, at the same time, blood lactate
concentrations and blood gases including pH, and base
excess.
Urine output and haemodynamic data
We reviewed the haemodynamic data before, and 6, 12,
and 24 h after CM injection and on days 2 and 3. At
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these times, we recorded the mean arterial blood pres-
sure and central venous pressure. For each day, we cal-
culated the quantity of liquids administered (oral and
intravenous). Because hourly diuresis being followed in
ICU patients, we summed the amount of urine output
each 6 h post CM injection.
Diagnosis of CA-AKI
We identified cases of CA-AKI according to the defin-
ition proposed by Barrett and Parfrey [18]: increase in
serum creatinine by 25 % from baseline or a minimum
of 0.5 mg/dL within 3 days after CM administration.
The baseline creatinine was that measured on the day of
the injection.
We classified patients in relation to the RIFLE urine
output criteria [19]: -R (Risk): < 0.5 ml/kg/h for 6 h,- I
(Injury): < 0.5 ml/kg/h for 12 h -F (Failure): < 0.3 ml/kg/
h for 24 h or anuria for 12 h.
Statistical analysis
Data are presented as median values with [25–75th]
percentiles or number (%) as appropriate. We used
Mann–Whitney or Kruskal-Wallis one way analysis of
variance for comparisons between groups. Changes over
time in creatinine concentrations, urine output, mean
blood pressure and fluid intake were analyzed using a
Friedman repeated measures analysis. A p value <0.05
was considered as significant. To identify potential risk
factors for developing CA-AKI based on the definition
proposed by Barrett and Parfrey [18] or death, we per-
formed a logistic regression analysis including all vari-
ables with a difference at the significance level ≤0.2
between patients who did and did not develop CA-AKI.
Because of the largely non Gaussian distribution, the
square root value of the doses of vasopressors dose was
introduced in the logistic regression model. In cases in
which two covariates were highly correlated, only one of
the two covariates was included in the model. Results
are reported as odds ratios (ORs) with 95 % confidence
intervals.
Statistical analyses were performed using the SigmaStat
v 12.0 software package (Systat Software Inc, San Jose,




During the 3-year study period, 4548 patients were ad-
mitted to our ICU. Thousand six hundred forty patients
had a CT of whom 311 had a CT with CM or a coronary
angiography. After exclusion of 162 patients (Fig. 1), the
final analysis included 149 patients (98 CT and 51 cor-
onary angiography).
The patients’ characteristics are summarized in Table 1.
Their median age was 64 [56–72] years, 62 % were male,
and the median APACHE II score was 20 [14–25].
Twenty eight percent had diabetes and 70 % had cardio-
vascular risk factors. The majority of the admissions
were for medical reasons (75.8 %). The median ICU
length of stay was 12 [7–21] days and ICU mortality was
35 %.
Diagnosis of CA-AKI
There were 23 cases of CA-AKI (15.4 %) in our cohort,
based on an increase in serum creatinine from 1.08
[0.61–1.34] mg/dL before CM injection to 1.43 [0.82–
2.13] mg/dL at day 3 (p < 0.001) (Fig. 2a). In contrast,
creatinine concentrations decreased overtime in patients
without CA-AKI (from 0.89 [0.64–1.10] to 0.70 [0.54–
0.92] mg/dL, p < 0.05; Fig. 2b). Thirteen of these cases
were in patients who had a CT scan (13.3 % of all pa-
tients who underwent a CT with CM) and ten in pa-
tients who had undergone coronary angiography (19.7 %
of all patients who underwent a coronary angiography).
Comparisons of clinical characteristics and biological
data in patients who developed CA-AKI and those who
did not are shown in Table 2. At the time of CM injec-
tion, urea and serum creatinine concentrations were
comparable in the two groups. More patients who devel-
oped CA-AKI needed RRT (13 vs 2 %, p = 0.02) and CA-
AKI was associated with higher ICU mortality (52 versus
4548 ICU 
admission
1329 CT  Scan 
without CM 
injection






Missing data n= 13
New CT and/or angio in less 72 h n= 40
Decision of RRT before CT n= 32
ICU stay < 72 h n= 67
Surgery in less 72 h n= 4










CT Scan or 
coronary 
angiography
Fig. 1 Flow chart of the patients included in the study
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19 %, p < 0.001). Although mean blood pressure remained
stable during the study period in patients who developed
CA-AKI, values were significantly lower already after 6 h
post CM injection and during the study period compared
to patients who did not develop CA-AKI (Table 2).
Urinary output
Fourteen of the 23 patients who developed CA-AKI
(61 %) had altered urine output during the study period
(1 “R”, 5 “I” and 8 “F” criteria from the RIFLE); in 10 of
these 14 patients (70 %), the decreased urine output was
noted before or at the same time as the increased serum
creatinine concentrations.
Forty-five patients (30.2 %) had at least one RIFLE
urine output criterion during the study period. Fourteen
of these 45 developed CA-AKI, based on the creatinine
criteria [18], associated with at least one RIFLE urine
output criterion. Thus, 31 of these 45 patients had only
RIFLE urine output criterion during the three days of
the study period.
The sensitivity and specificity of the RIFLE urine
output criteria as a screening test for CA-AKI as de-
fined by Barrett and Parfrey [18], were 39.1 and
67.9 %, respectively, with a positive predictive value
of 50.0 % and a negative predictive value of 87.2 %.
The positive likelihood was 1.2 and the negative like-
lihood was 0.90.
Table 1 Clinical, biological and haemodynamic characteristics
of the total population (n = 149) before CM injection
Age (years) 64 [56–72]
Sex (male, %) 92 (62)
ICU admission diagnosis (medical/surgical) 113/36
APACHE II score 20 [14–25]
Weight (kg) 78.0 [70.0–90.0]
Diabetes mellitus (%) 41 (27.5)
Cardiovascular risk factors (%) 104 (69.8)
Need for renal replacement (%) 6 (4)
Length of ICU stay (days) 12 [7–21]
ICU mortality (%) 35 (23.5)
Haematocrit (%) 31.4 [27.1–38.3]
Urea (mg/dL) 44.4 [32.0–58.1]
Creatinine (mg/dL) 0.91 [0.64–1.13]
MDRD (mL/min/1.73 m2) 77.7 [54.5–113.4]
Patients with creatinine ≥1.5 mg/dL (%) 15 (10)
pH 7.40 [7.33–7.46]
BE (meq/L) 0.00 [−3.00–4.25]
HCO3 (mg/dL) 24.8 [21.6–29.2]
Na (mEq/L) 140 ± 5
Lactate (mmol/L) 0.5 [0.4–0.8]
Nephropathy prevention (%) 29 (19.5)
Mean blood pressure before CM injection (mmHg) 81 [71–93]
CVP (mmHg) 9 [6–12]
Maximal vasopressor dose (mcg/kg/min) 0.00 [0.00–0.08]
Fluid intake, day 0 (mL) 2830 [2114–3621]
Doses of CM (ml/kg) 1.6 [1.31–2.29]
Nephrotoxic drugs (%) 66 (44.3)




Fig. 2 Time course of serum creatinine concentrations in patients
who developed CA-AKI (a) and those who did not (b). Friedman
Repeated Measures Analysis
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We also compared the clinical, biological and
haemodynamic data in patients with CA-AKI defined
by Barrett and Parfrey (n = 9), those with CA-AKI
and RIFLE urine output criteria (n = 14), those with
RIFLE urine output criteria alone (n = 31), and those
without changes in urine output or creatinine (n = 95)
(Table 3). Patients with CA-AKI and RIFLE urine out-
put criteria had a higher weight, a higher baseline
Table 2 Comparisons of clinical, biological and haemodynamic characteristics between patients who developed or not CA-AKI
CA-AKI (n = 23) No CA-AKI (n = 126) P value
Age (years) 65 [55–78] 64 [56–72] 0.43
Sex (male/female) 16/7 76/50 0.41
ICU admission diagnosis (medical/surgical) 20/3 93/33 0.18
APACHE II score 25 [18–30] 19 [14–24] 0.006
Weight (kg) 80 [70–90] 78 [70–90] 0.91
Diabetes mellitus (%) 6 (26) 35 (28) 0.87
Cardiovascular risk factors (%) 17 (74) 87 (69) 0.64
Need for renal replacement (%) 3 (13) 3 (2) 0.02
Length of ICU stay (days) 13 [6–18] 12 [7–22] 0.99
ICU mortality (%) 12 (52) 23 (19) <0.001
Haematocrit (%) 31.5 [27.3–33.5] 31.4 [27.0–38.2] 0.78
Urea (mg/dL) 47.9 [35.2–56.4] 44.1 [31.8–58.5] 0.63
Creatinine (mg/dL) 1.08 [0.61–1.34] 0.89 [0.64–1.10] 0.26
MDRD (mL/min/1.73 m2) 61.0 [49.4–105.0] 79.4 [57.4–116.0] 0.15
Patients with creatinine ≥1.5 mg/dL (%) 3 (13 %) 12 (9.5 %) 0.61
pH 7.37 [7.28–7.47] 7.40 [7.33–7.46] 0.39
BE (meq/L) −1.5 [−4.0 − 3.0] 0.0 [−3.0–4.0] 0.38
HCO3 (mg/dL) 23.6 [20.7–31.3] 25.3 [23.0–29.3] 0.54
Na (mEq/L) 138 [134–142] 139 [137–143] 0.14
Lactate (mmol/L) 0.7 [0.5–1.3] 0.5 [0.4–0.8] 0.02
Nephropathy prevention (%) 3 (13) 26 (20) 0.40
Mean blood pressure before CM (mmHg) 79 [62–89] 81 [72–93] 0.15
Mean blood pressure at 6 h post CM injection (mmHg) 73 [67–82] 81 [70–94] 0.056
Mean blood pressure at 12 h post CM injection (mmHg) 73 [66–76] 77 [71–88] 0.012
Mean blood pressure at 24 h post CM injection (mmHg) 78 [71–87] 79 [70–94] 0.092
Mean blood pressure at 48 h post CM injection (mmHg) 75 [68–90] 85 [77–98] 0.001
Mean blood pressure at 72 h post CM injection (mmHg) 76 [70–87] 85 [75–100] 0.008
CVP before CM (mmHg) 13 [8–14] 9 [6–11] 0.12
Maximal vasopressor dose before CM (mcg/kg/min) 0.07 [0.00–0.20] 0.00 [0.00–0.05] 0.001
Maximal vasopressor dose day 1 (mcg/kg/min) 0.07 [0.00–0.26] 0.00 [0.00–0.00] <0.001
Maximal vasopressor dose day 2 (mcg/kg/min) 0.04 [0.00–0.35] 0.00 [0.00–0.00] <0.001
Maximal vasopressor dose day 3 (mcg/kg/min) 0.03 [0.00–0.29] 0.00 [0.00–0.00] <0.001
Doses of CM (ml/kg) 1.71 [1.44–3.47] 1.60 [1.30–2.00] 0. 14
Nephrotoxic drugs (%) 9 (39.1) 57 (46.3) 0.59
Diuretics on day of CM injection (%) 5 (21.7) 19 (15.1) 0.43
Fluid intake, day 0 (ml) 2950 [1975–3060] 2825 [1975–3060] 0.74
Fluid intake, day 1 (ml) 2982 [2047–3945] 2948 [2080–3685] 0.71
Fluid intake, day 2 (ml) 2455 [1807–3756] 2648 [2010–3305] 0.99
Fluid intake, day 3 (ml) 2695 [1877–3678] 2340 [1643–3283] 0.34
Mann–Whitney Rank Sum test, t-test or chi2; BE base excess
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Table 3 Comparisons of clinical, biological and haemodynamic characteristics between patients who developed CA-AKI based on creatin-
ine levels, CA-AKI with RIFLE urinary output criteria, with RIFLE urine output criteria only, or without CA-AKI or RIFLE urine output criteria
CA-AKI and RIFLE (n = 14) CA-AKI (n = 9) Only RIFLE (n = 31) No CA-AKI (n = 95) P value
Age (years) 73 [61–80] 60 [48–67] 68 [57–75] 63 [55–71] 0.08
Sex (male/female) 10/4 6/3 22/9 55/40 0.55
ICU admission diagnosis (medical/surgical) 11/3* 7/2 29/2* 77/18 0.41
APACHE II score 26 [20–30]* 21 [17–28] 18 [11–26] 20 [14–23] 0.04
Weight (kg) 80 [74–90] 72 [60–88] 84 [75–95]* 75 [65–86] 0.05
Diabetes mellitus (%) 4 (29) 2 (22) 9 (29) 26 (27) 0.98
Nephrotoxic drugs 5 (36) 4 (44) 14 (45) 43 (45) 0.92
Cardiovascular risk factors (%) 11 (79) 6 (75) 23 (74) 65 (68) 0.86
Need for renal replacement (%) 3 (21)* 0 (0) 3 (10)* 0 (0) <0.001
Length of ICU stay (days) 15 [12–18] 10 [6–19] 8 [5–21] 12 [8–23] 0.42
ICU mortality (%) 9 (64)* 3 (33) 9 (29) 14 (15) <0.001
Haematocrit (%) 32 .2 [29.2–40.2] 28.5 [24.8–33.0] 32.1 [26.9–40.8] 30.6 [27.1–36.6] 0.37
Urea (mg/dL) 50 [42–57] 40 [31–54] 40 [32–60] 44 [32–58] 0.57
Creatinine (mg/dL) 1.18 [1.00–1.40]* 0.80 [0.45–1.10] 0.98 [0.74–1.18] 0.84 [0.62–1.08] 0.03
MDRD mL/min/1.73 m2 52 [46–71] 80 [66–173] 76 [52–92] 82 [59–128] 0.06
Patients with creatinine ≥1.5 mg/dL 1 (9 %) 1 (14 %) 4 (12.9 %) 9 (9.5 %) 0.93
pH 7.37 [7.30–7.42] 7.42 [7.27–7.48] 7.36 [7.30–7.42] 7.42 [7.33–7.46] 0.08
BE (meq/L) −2 [−6–2] 1 [−3–7] −1 [−4–0] 1 [−2–5] 0.08
HCO3 (mmoL/L) 22.9 [20.7–25.2] 25.0 [23.5–31.4] 24.0 [21.4–27.8] 25.7 [22.0–30.3] 0.29
Na (mEq/L) 140 [136–142] 138 [134–140] 139 [137–143] 140 [137–143] 0.19
CPK (UI/mL) 171 [91–854] 203 [11–376] 199 [49–604] 117 [44–348] 0.32
CRP (mg/dL) 15.6 [6.6–22.8] 8.7 [3.6–17.3] 7.4 [0.5–13.0] 9.3 [2.5–18.4] 0.13
Lactate (mmol/L) 1.0 [0.6–1.3] 0.6 [0.5–0.9] 0.4 [0.4–0.8] 0.5 [0.5–0.7] 0.11
Nephropathy prevention (%) 2 (14.2) 0 (0) 6 (19.4) 21 (22) 0.41
Mean blood pressure before CM (mmHg) 80 [64–94] 70 [62–87] 84 [74–91] 81 [71–94] 0.51
Mean blood pressure at 6 h (mmHg) 72 [66–88] 72 [60–79] 77 [68–88] 81 [71–96] 0.10
Mean blood pressure at 12 h (mmHg) 73 [64–74]* 74 [68–80] 74 [69–79] 79 [70–88] 0.02
Mean blood pressure at day 1 (mmHg) 71 [65–74]* 76 [69–80] 74 [68–83] 85 [74–97] <0.001
Mean blood pressure at day 2 (mmHg) 67 [64–77]* 74 [68–77]* 79 [71–86]* 90 [79–98] <0.001
Mean blood pressure at day 3 (mmHg) 76 [69–88]* 71 [65–85]* 77 [69–88]* 88 [77–100] <0.001
CVP before CM (mmHg) 10 [6–14] 13 (11–14] 10 [8–11] 9 [5–11] 0.14
Maximal vasopressor dose on the day of CM
(mcg/kg/min)
0.12 [0.00–0.20]* vs no 0.00 [0.00–0.15] 0.04 [0.00–0.12] 0.00 [0.00–0.00] 0.004
Maximal vasopressor dose, day 1 (mcg/kg/min) 0.10 [0.05–0.40]* 0.00 [0.00–0.06] 0.00 [0.00–0.06] 0.00 [0.00–0.00] <0.001
Maximal vasopressor dose, day 2 (mcg/kg/min) 0.19 [0.00–0.40]* 0.00 [0.00–0.04] 0.00 [0.00–0.08] 0.00 [0.00–0.00] <0.001
Maximal vasopressor dose, day 3 (mcg/kg/min) 0.15 [0.00–0.30]* 0.00 [0.00–0.09] 0.00 [0.00–0.01] 0.00 [0.00–0.00] <0.001
Doses of CM (ml/kg) 1.54 [1.47–5.38] 1.64 [1.33–1.85] 1.53 [1.17–1.61] 1.60 [1.21–1.85] 0.32
Diuretics on day of CM injection (%) 1 (9 %) 5 (71 %)* 3 (12 %) 7 (13 %) <0.001
Fluid intake, day 0 (ml) 3015 [2200–3885] 2495 [1774–3030] 2600 [2058–3516] 2830 [2124–3814] 0.65
Fluid intake, day 1 (ml) 3371 [2125–4184] 3371 [2125–4184] 3085 [2005–3748] 2865 [2098–3676] 0.49
Fluid intake, day 2 (ml) 3069 [1786–3780] 2090 [1730–3369] 2810 [2186–3124] 2550 [1949–3395] 0.78
Fluid intake, day 3 (ml) 2640 [1738–3811] 2750 [1820–3308] 2285 [1628–3103] 2465 [1690–3360] 0.63
Kruskal Wallis One way of variance on ranks with Dunn test correction
BE base excess
*p value <0.05 versus no CA-AKI
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creatinine concentration, need more RRT and higher
mortality compared to patients without CA-AKI or
RIFLE urine output criteria (Table 3). Despite higher
doses of vasopressors, mean blood pressure was sig-
nificantly lower with CA-AKI and RIFLE urine output
criteria from 12 h post CM injection to days 3 com-
pared to patients without CA-AKI and RIFLE urine
output criteria (Table 3). Patients with only RIFLE
criteria have the same length of ICU stay and ICU
mortality than others but need more RRT than pa-
tients with CA-AKI based on creatinine levels, or
without CA-AKI.
Finally, using a logistic regression analysis we assessed
the prognostic parameters for development of CA-AKI
and mortality (Tables 4 and 5). For the development of
CA-AKI (Table 4), these factors were the APACHE II
score, dose of CM injected by body weight, mean arterial
blood pressure before CM injection, square root max-
imum dose of norepinephrine the day of CM injection,
lactate and sodium concentrations the day of CM injec-
tion. For the mortality (Table 5), we included the same
parameters plus the presence of CA-AKI. In the first
model, only the square root of the dose of vasopressors
before CM injection was significantly associated with the
development of CA-AKI: OR 10.80 (1.87–62.34); p =
0.008 (Table 4). For the prediction of mortality, APA-
CHE II score, dose of CM injected by body weight, CVP
before CM injection, and presence of CA-AKI were sig-
nificant (Table 5).
Discussion
Our hypothesis was that urine output could be a predict-
ive marker for detection of CA-AKI. To evaluate this
possibility, we used the urine output criteria of the RI-
FLE classification [19]. We observed that the presence of
at least one RIFLE urine output criterion had low sensi-
tivity and specificity (39.1 and 67.9 %), a low positive
predictive value of 50.0 % and a negative predictive value
of 87.2 %. Only 57 % of the patients presented a “F” cri-
teria of the RIFLE classification. Moreover, oliguria was
observed prior to CA-AKI in only 9/23 patients (39 %).
Thus, more than 60 % of the patients, oliguria developed
when the creatinine concentration was already increasing,
limiting the possibility of modifying therapy. Although oli-
guria may be an interesting marker of development of
AKI in some situations [28], it is, therefore, probably of
limited value in CA-AKI.
Despite the widespread use of CM injections in ICU
patients, the epidemiology of CA-AKI is poorly de-
scribed. In our retrospective study of 149 patients who
were given a CM injection, we identified 23 patients
(15.4 %) who developed CA-AKI during their ICU stay
based on the definition of Barrett and Parfrey [18]. CA-
AKI was associated with higher rates of renal replace-
ment therapy (13 %) and increased ICU mortality
(52 %). This frequency of CA-AKI is high, but in agree-
ment with other recent studies. In a monocenter retro-
spective study over a 4.5 year period, Hoste et al. [15]
reported that 16.3 % of the 787 patients receiving CM
for CT scan or non-coronary angiography, developed
CA-AKI based on creatinine concentrations [15]. Valette
et al. [29] reported an incidence of 17 % in a population
of surgical patients after CT scan, although 33 % of these
patients had received another CM injection within a 72-
h period, which may perhaps have resulted in an over-
estimation of the incidence of CA-AKI in this study
[29]. For these reasons, we excluded patients who had a
second CM injection. In contrast, Cely et al. identified
only a 2 % occurrence of CA-AKI [14]. This large vari-
ation between studies is perhaps due to different defini-
tions used for CA-AKI. Indeed, we used the same
definition as Hoste et al. [15], based on the increase in
serum creatinine of 25 % within 72 h after injection,
whereas Cely et al. [14] used a decrease of 33 % of the
measured creatinine clearance. Another difference with
previous studies is the large number of patients in our
study (34.2 %) who received CM for coronary
Table 4 Logistic regression to identify potential risk factors for
development of CA-AKI
Risk factors OR (IC 95 %) P
value
APACHE II score 1.02 (0.98–1.07) 0.33
Dose of CM injected by body weight 1.02 (0.80–1.30) 0.89
Na before CM 0.94 (0.88–1.01) 0.11
Mean arterial blood pressure before CM
injection
1.00 (0.98–1.03) 0.81
Square root of the dose of vasopressors
before CM injection
10.80 (1.87–62.34) 0.008
Lactate 1.00 (0.98–1.02) 0.99
CVP before CM injection 1.00 (1.00–1.01) 0.38
OR odds ratio and 95 % confidence intervals
Na sodium concentration
Table 5 Logistic regression to identify potential risk factors for
mortality
Risk factors OR (IC 95 %) P value
APACHE II score 1.15 (1.07–1.23) <0.0001
Presence of CA-AKI 0.25 (0.09–0.68) 0.007
Dose of CM 1.37 (1.00–1.86) 0.05
Na before CM 1.08 (0.97–1.20) 0.15
Mean arterial blood pressure before CM
injection
1.00 (0.9−1.02) 0.29
Square root of the dose of vasopressors
before CM injection
1.96 (0.28–13.64) 0.50
Lactate 1.01 (0.99–1.04) 0.24
CVP before CM injection 0.84 (0.71–0.94) 0.04
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angiography. Indeed, this population is more at risk of
developing CA-AKI [16] for several reasons: First, the
risk may be increased by the coronary procedure itself,
as a result of low blood pressure and release of athero-
embolic material during catheterization in the arterial
circulation [16]. Moreover, the coronary procedure was
performed after cardiac arrest in most cases, which may
per se induce AKI, although this association remains
controversial [30, 31]. Kidney function before CM
injection (creatinine, metabolic acidosis) was more al-
tered in our coronary angiography patients than in our
CT patients; the coronary angiography patients were
also more haemodynamically unstable during the survey
period and received more CM/body weight. It thus
seems logical to assume that an injection of CM could
worsen the risk of CA-AKI by additional vasoconstric-
tion and tubular injury.
We observed that mean blood pressure was lower at
12 h after CM injection and on day 2 and 3 in patients
who developed CA-AKI compared to patients who did
not. Nevertheless, mean blood pressure prior to CM in-
jection was not significantly associated with CA-AKI in
logistic regression. Our resuscitation process is based on
recommendations for prevention of AKI in sepsis [5, 6,
32]. Indeed, Bourgoin et al. [5] observed no difference in
diuresis, creatinine concentration and clearance in 28
patients with septic shock with a mean blood pressure of
65 mmHg compared to 85 mmHg [5]. Nevertheless, this
study was performed over 8 h and no data at later time-
points (for example, 3 days) were reported. Albanese et
al. [6] showed, in a prospective open label study, that
norepinephrine increased urine output and decreased
serum creatinine in septic but not in non-septic patients
(head trauma with normal renal function) [6]. Moreover,
it is possible that patients with chronic hypertension, as
observed in 69.8 % of our population who developed
CA-AKI, may need a higher mean blood pressure target
[33]. Indeed, Asfar et al. [34] observed in a large septic
population that higher levels of mean blood pressure
(80–85 mmHg) was associated with less increase of cre-
atinine levels and need for RRT in chronic hypertensive
patients. Thus, the level of mean blood pressure was
perhaps too low and may have contributed to the devel-
opment of CA-AKI. This suggestion needs confirmation
in prospective studies.
Our study has some limitations. First, the study was
monocenter and retrospective. We have included only
3 % of the patients admitted in the ICU during the study
period due to the strict inclusion and exclusion criteria.
For these reasons, results should be taken with care to
extra polate to other ICUs. Second, only 19.5 % of the
patients who developed CA-AKI received preventive
therapy. Indeed, a routine protocol was not applied to all
patients in our ICU, as is proposed by the ESICM [35];
in contrast, only patients at risk of developing CA-AKI
received preventive therapy. Discerning which patients
are at risk can be difficult as shown by our data; more-
over, urgent need for CT or angiography may limit the
time available for applying a protocol, such as bicarbon-
ate perfusion or hydration. Nevertheless, patients were
already resuscitated before CM injection as suggested by
the lactate concentrations, the mean arterial pressure
and the CVP reported (Table 1).
Third, we investigated the potential deleterious effect
of CM injection, but other factors may influence renal
function in critical illness.
Fourth, as reported by several authors [15, 36, 37],
studies reported the concept that AKI is not contrast-
induced, and is an overstimated problem, because con-
trol patients without exposure to iodinated CM had a
comparable incidence of AKI [36, 37].
Conclusions
In conclusion, we have confirmed that CA-AKI is a fre-
quent complication in ICU patients undergoing CT or
coronary angiography and is associated with greater
need for extra-renal epuration and increased mortality.
The predictive value of the RIFLE urine output criteria
for the development of CA-AKI diagnosed based on cre-
atinine concentrations is low and limits their use for
assessing the effects of therapeutic interventions on the
development and progression of AKI.
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